No Data
No Data
Watching Mirum Pharmaceuticals; Shares Trading Higher After Circulation Of Unconfirmed Rumor That Swedish Orphan Biovitrum AB (Sobi) Has Proposed A Takeover
Buy Rating Affirmed for Mirum Pharmaceuticals Amidst Label Expansion and Positive EU Authorization
Mirum Pharmaceuticals Gets FDA Label Expansion Approval for Liver Disease Treatment; Shares Jump
Express News | Mirum’s Livmarli Now Approved for Pfic in Patients 12 Months and Older
The 9.9% Return This Week Takes Mirum Pharmaceuticals' (NASDAQ:MIRM) Shareholders Five-year Gains to 183%
JMP Securities Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $69
JMP Securities analyst Jonathan Wolleben maintains $Mirum Pharmaceuticals(MIRM.US)$ with a buy rating, and maintains the target price at $69.According to TipRanks data, the analyst has a success